U.S. Cancer Death Rates Have Continued to Decline
The latest national report highlights significant progress in lung cancer outcomes and survival rates.
Updated on Sept. 22, 2026 in Cancer
Live Poll
Is the quality of healthcare and cancer prevention in your area getting better?
The Annual Report to the Nation on the Status of Cancer has documented a sustained drop in U.S. cancer death rates. This positive trend is primarily driven by substantial improvements in lung cancer survival and a decline in tobacco usage.
Why it matters
The reduction in cancer mortality reflects decades of effort in smoking cessation, alongside advancements in early detection and targeted medical treatments. These milestones demonstrate the long-term impact of public health initiatives and modern oncology on survival outcomes.
Cancer death rates declined among all racial and ethnic groups, with lung cancer rates dropping 4.7% for males and 3% for females annually from 2019 to 2023. Meanwhile, the five-year relative survival for lung cancer reached 30.1% as of 2018.
The players
The Annual Report to the Nation on the Status of Cancer
This report serves as a major collaborative publication providing comprehensive data on cancer trends and public health outcomes in the United States.
The details
Declines in smoking incidence observed from 1970 through 2022 provided a strong foundation for reducing lung cancer mortality. Clinical progress, including wider access to biomarker testing and immunotherapy, has further bolstered survival rates across the nation.
Timeline
1970-2022 marked the period of smoking reduction that contributed to averted cancer deaths.
2004-2023 served as the analytical window for overall cancer mortality trends.
2019-2023 was the calculation period for overall and lung cancer death rates.
2024 saw adult cigarette smoking prevalence fall to 9.9%.
2025 is the year by which 22 states mandated insurance coverage for biomarker testing.
The Big Picture
This report tracks the multi-decade outcomes of the National Cancer Act of 1971, measuring the tangible impact of sustained federal investment in oncological research and prevention. It quantifies the cumulative success of long-term strategic investments in cancer research and public policy.
Increased access to biomarker testing and screening, now supported by state mandates in 22 regions, provides more personalized treatment options for patients. These shifts in medical policy allow for earlier interventions that significantly improve the odds of successful cancer recovery.
The takeaway
The continued decline in cancer mortality highlights the effectiveness of combined efforts in tobacco prevention and advanced clinical diagnostics. Readers should prioritize routine cancer screenings and consult with healthcare providers about available biomarker testing options.
Further reading
For more information on national health trends, visit the Cancer section.
Live Poll
Is the quality of healthcare and cancer prevention in your area getting better?
